Johan Aschan
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Journal: Future oncology (London, England)
Published: March 07, 2020
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
Journal: Haematologica
Published: February 09, 2018
Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT).
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
Journal: PloS one
Published: April 09, 2014
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
Journal: European journal of haematology
Published: October 08, 2013
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Journal: British journal of haematology
Published: May 20, 2013
A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation.
Journal: Journal of internal medicine
Published: February 26, 2013
A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.
Journal: Acta haematologica
Published: June 12, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026